Takeda Pharmaceutical Co Ltd (NYSE:TAK) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Takeda Pharmaceutical Co Ltd (NYSE:TAK) have been assigned an average rating of “Hold” from the six brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $19.50.

Several research analysts have commented on TAK shares. ValuEngine downgraded Takeda Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. Jefferies Financial Group began coverage on Takeda Pharmaceutical in a research report on Tuesday, September 24th. They issued a “buy” rating for the company. Zacks Investment Research raised Takeda Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, November 5th. Daiwa Capital Markets downgraded shares of Takeda Pharmaceutical from an “outperform” rating to a “neutral” rating in a research note on Thursday, August 15th. Finally, Cowen started coverage on shares of Takeda Pharmaceutical in a research report on Friday, November 1st. They set a “market perform” rating and a $19.50 target price on the stock.

Shares of NYSE:TAK traded down $0.18 during midday trading on Tuesday, hitting $20.38. The company’s stock had a trading volume of 1,217,500 shares, compared to its average volume of 2,366,127. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.94 and a current ratio of 1.45. The stock’s 50 day simple moving average is $19.16 and its 200 day simple moving average is $17.78. The stock has a market capitalization of $63.28 billion, a price-to-earnings ratio of 39.96 and a beta of 0.76. Takeda Pharmaceutical has a fifty-two week low of $15.50 and a fifty-two week high of $21.61.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Thursday, October 31st. The company reported $0.59 earnings per share for the quarter. Takeda Pharmaceutical had a return on equity of 12.52% and a net margin of 3.66%. The business had revenue of $7.56 billion during the quarter. As a group, analysts anticipate that Takeda Pharmaceutical will post 1.99 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TAK. Checchi Capital Advisers LLC increased its stake in Takeda Pharmaceutical by 3.9% during the third quarter. Checchi Capital Advisers LLC now owns 14,477 shares of the company’s stock valued at $249,000 after acquiring an additional 547 shares during the period. Coastal Investment Advisors Inc. grew its holdings in shares of Takeda Pharmaceutical by 59.8% during the 2nd quarter. Coastal Investment Advisors Inc. now owns 1,718 shares of the company’s stock worth $32,000 after purchasing an additional 643 shares in the last quarter. Stephens Inc. AR grew its holdings in shares of Takeda Pharmaceutical by 6.7% during the 3rd quarter. Stephens Inc. AR now owns 11,704 shares of the company’s stock worth $201,000 after purchasing an additional 732 shares in the last quarter. HighTower Advisors LLC increased its position in shares of Takeda Pharmaceutical by 3.2% during the second quarter. HighTower Advisors LLC now owns 29,939 shares of the company’s stock valued at $534,000 after purchasing an additional 919 shares during the period. Finally, SRS Capital Advisors Inc. increased its position in shares of Takeda Pharmaceutical by 83.3% during the third quarter. SRS Capital Advisors Inc. now owns 2,200 shares of the company’s stock valued at $38,000 after purchasing an additional 1,000 shares during the period. Institutional investors and hedge funds own 4.58% of the company’s stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.

Featured Article: Monthly Dividend Stocks Can Provide Solid Income

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.